Concentra Q3 2026 Earnings: Margin Expansion Supports Raised Guidance

Concentra (NYSE: CON) reported Q3 2026 revenue of $622.1 million, up 8.6% year over year, while diluted EPS increased to $0.52 from $0.38. For the quarter ended September 30, net income rose 36.0% and adjusted EBITDA margin reached 22.5%, supported by higher patient visits and revenue per visit. Quarterly operating cash flow and free cash flow declined, but the company raised its full-year 2026 guidance.

Core Results

Revenue growth reflected both higher activity and more revenue generated per visit. Daily patient visits increased 4.9%, while revenue per visit rose 3.3%. Cost of services grew 5.2%, below the 8.6% increase in revenue, helping operating income rise 21.9%; however, general and administrative expenses increased faster than revenue at 15.2%.

GAAP net income margin expanded to 10.9% from 8.7%, while adjusted EBITDA margin increased to 22.5% from approximately 20.7%. Lower interest expense, which fell to $25.2 million from $28.7 million, also contributed to the increase in pretax income. Adjusted EPS was $0.52, up 33.3% year over year.

Adjusted EBITDA and free cash flow are non-GAAP measures reported by the company.

Operating Trends and Footprint

Concentra recorded 3,731,956 patient visits during the quarter, equivalent to 58,312 visits per day, compared with 55,589 per day a year earlier. Revenue per visit increased to $152.14 from $147.31. The combination of higher volume and higher revenue per visit broadly aligned with the overall revenue increase.

The company ended the quarter with 639 occupational health centers, up from 628 a year earlier, and 423 onsite health clinics, compared with 413. During the quarter, Concentra opened three new occupational health centers in Kansas City, Boise, and Daytona Beach and acquired a four-center occupational health practice in Minnesota.

Higher Earnings Did Not Translate Into Higher Quarterly Cash Flow

Despite the increase in net income, operating cash flow declined by $8.8 million year over year. The cash flow statement showed a $20.5 million use of cash from accounts receivable, compared with $7.6 million a year earlier, and a $79.1 million use from other assets, compared with a $2.2 million source of cash. A $59.7 million source from accounts payable and accrued liabilities partially offset those movements.

Free cash flow consequently fell to $32.2 million from $40.2 million. Concentra spent $22.5 million on capital expenditures and $6.2 million on acquisitions during the quarter, partly offset by $2.8 million of proceeds from asset sales.

Financing activities used $98.2 million, primarily for $52.4 million of term-loan repayments, $34.7 million of share repurchases, and $8.0 million of dividends. Cash declined by $72.2 million during the quarter to $85.8 million. Total debt was $1.52 billion, and net leverage stood at 2.90x, within the company’s credit agreement covenant.

Concentra repurchased 1.0 million shares during the quarter for $34.65 million. Its board subsequently authorized an additional repurchase program of up to $250 million with no expiration date, although the authorization does not require the company to buy shares. The board also declared a quarterly dividend of $0.0625 per share, payable on or about December 4, 2026, to shareholders of record on November 19.

2026 Guidance

Concentra characterized its updated full-year outlook as a guidance increase. The release did not provide the previous ranges, so the size of the revision cannot be quantified.

Capital expenditure guidance excludes acquisitions and is net of proceeds from asset sales.

Recent Insider Transactions

The supplied insider dataset lists four indirect sales by director Robert A. Ortenzio between May and August 2026, with a combined reported value of approximately $14.6 million. However, the same dataset’s six-month summary reports zero sale transactions, so the two sections are internally inconsistent and should be compared with the underlying regulatory filings.

The six transactions reported at zero value were gifts or equity awards rather than open-market purchases.

Risks Investors Need to Watch

• Cash conversion: Operating cash flow and free cash flow declined even as earnings increased, making movements in receivables and other operating assets important to monitor.
• Margin durability: Cost of services grew more slowly than revenue this quarter, but the company identifies labor costs and its ability to secure reimbursement increases that keep pace with inflation as continuing risks.
• Volume sensitivity: Patient visits were a major revenue driver. Changes in work-related injury frequency or relationships with employers, payors, and provider networks could affect future volumes.
• Leverage and capital deployment: Concentra ended the quarter with $1.52 billion of debt and 2.90x net leverage while using cash for debt repayment, repurchases, dividends, acquisitions, and new locations.

Summary

Concentra’s Q3 2026 results combined higher patient volumes and revenue per visit with slower growth in service costs, producing faster operating income growth and wider margins. Cash conversion was weaker because of operating asset and liability movements, even as the company repaid debt and returned capital to shareholders. The next points to monitor are performance against the raised full-year guidance, the durability of margin expansion, and whether earnings growth converts into stronger free cash flow.